

J Rheumatol 2014;91;1-85
<http://www.jrheum.org/content/91.citation>

1. Sign up for TOCs and other alerts
<http://www.jrheum.org/alerts>
2. Information on Subscriptions
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

The Journal of Rheumatology

VOLUME 41: SUPPLEMENT 91

jrheum.org

MAY 2014

Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence

Introduction Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence <i>F. Cantini, D. Goletti</i>	1
Update on the Epidemiology of Tuberculosis in Italy <i>M. Conversano</i>	4
The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics <i>G. Delogu, D. Goletti</i>	11
Cellular and Humoral Immune Responses During Tuberculosis Infection: Useful Knowledge in the Era of Biological Agents <i>A. Matucci, E. Maggi, A. Vultaggio</i>	17
Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches <i>D. Goletti, A. Sanduzzi, G. Delogu</i>	24
Diagnostic Accuracy of Chest Radiography for the Diagnosis of Tuberculosis (TB) and Its Role in the Detection of Latent TB Infection: a Systematic Review <i>R. Piccazzo, F. Paparo, G. Garlaschi</i>	32
Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations <i>F. Iannone, F. Cantini, G. Lapadula</i>	41
Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance <i>F. Cantini, L. Niccoli, D. Goletti</i>	47
Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries <i>F. Cantini, L. Niccoli, D. Goletti</i>	56
Tuberculosis Reactivation Risk in Dermatology <i>L. Pescitelli, F. Ricceri, F. Prignano</i>	65
Current Treatment Options for Latent Tuberculosis Infection <i>M. Bocchino, A. Matarese, A. Sanduzzi</i>	71
Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment <i>F. Cantini, F. Prignano, D. Goletti</i>	78
Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation? <i>L. Trieste, G. Turchetti</i>	83